Furthermore, the use of IFN-α as therapy in patients with HAM has been shown to reduce the percentage of inflammatory cells in the cerebrospinal fluid and blood, contributing to the clinical improvement of the patient (Feng et al., 2004). This evidence concerns the gene IFNA17 and tropical spastic paraparesis.